Bristol Myers Squibb Company Announces Quarterly Dividend of $0.62 (NYSE:BMY)

Key Points

• Bristol Myers Squibb declared a quarterly dividend of $0.62 per share, with an annualized yield of 5.4%, payable on November 3rd to shareholders of record on October 3rd.
• The company reported a net margin of 10.58% and a return on equity of 80.04% in its latest quarterly earnings, with revenues of $12.27 billion exceeding analyst expectations.
• Bristol Myers Squibb has a dividend payout ratio of 40.9% and is projected to earn $6.09 per share in the next year, indicating a solid capacity to sustain its dividend payments.

Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) declared a quarterly dividend on Wednesday, September 17th, RTT News reports. Shareholders of record on Friday, October 3rd will be given a dividend of 0.62 per share by the biopharmaceutical company on Monday, November 3rd. This represents a c) annualized dividend and a yield of 5.4%.

Bristol Myers Squibb has a dividend payout ratio of 40.9% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Bristol Myers Squibb to earn $6.09 per share next year, which means the company should continue to be able to cover its $2.48 annual dividend with an expected future payout ratio of 40.7%.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $46.30 on Wednesday. Bristol Myers Squibb has a 12-month low of $42.96 and a 12-month high of $63.33. The stock has a market cap of $94.24 billion, a P/E ratio of 18.67, a PEG ratio of 2.37 and a beta of 0.35. The company has a 50-day moving average price of $47.06 and a 200 day moving average price of $49.95. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. During the same period last year, the business earned $2.07 earnings per share. Bristol Myers Squibb's revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.